AQ
AQST.US Aquestive Therapeutics Inc
- Market cap
- USD 491M
- P/E
- -
- P/B
- 14.15x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AQST.US undervalued?
Graham numberThe Graham number of Aquestive Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aquestive Therapeutics Inc fundamental analysis
No fundamental analysis for Aquestive Therapeutics Inc yet.
Aquestive Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used f…
Full company profileAquestive Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aquestive Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 51.8M | 66.9M | 67.4M | 52.6M | 45.8M | 50.8M | 47.7M | 50.6M | 57.6M | 44.5M | 47.8M |
| Gross Profit | 35.4M | 47.1M | 46.4M | 32.2M | 32.9M | 35.8M | 28.3M | 29.8M | 39.7M | 27.4M | 33.0M |
| Operating Income | -847K | -113K | -48.9M | -52.7M | -42.9M | -34.7M | -42.1M | -15.1M | -30.8M | -69.7M | -35.9M |
| EBITDA | 2.95M | 2.57M | -50.4M | -54.0M | -39.3M | -45.1M | -39.6M | 1.18M | -26.6M | -66.1M | -49.8M |
| Net Income | -9.60M | -8.94M | -61.4M | -66.2M | -55.8M | -70.5M | -54.4M | -7.87M | -44.1M | -83.8M | -63.2M |
| EPS | -0.39 | -0.45 | -2.96 | -2.61 | -1.66 | -1.85 | -1.12 | -0.13 | -0.51 | -0.69 | -0.50 |
| Balance Sheet | |||||||||||
| Total Assets | 39.4M | 43.1M | 86.9M | 78.5M | 62.9M | 62.0M | 57.1M | 57.4M | 101M | 160M | 119M |
| Total Liabilities | 57.0M | 69.6M | 76.8M | 84.6M | 111M | 144M | 176M | 164M | 162M | 194M | 190M |
| Shareholders' Equity | -17.6M | -26.5M | 10.1M | -6.12M | -48.5M | -82.1M | -119M | -106M | -60.2M | -33.7M | -70.8M |
| Cash & Short-term Investments | 9.21M | 17.4M | 60.6M | 49.3M | 31.8M | 28.0M | 27.3M | 23.9M | 71.5M | 121M | 90.3M |
| Total Debt | 117M | 87.9M | 47.2M | 60.3M | 40.5M | 56.4M | 57.5M | 33.3M | 38.0M | 131M | 8.10M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.18M | 5.82M | -13.0M | -60.2M | -45.5M | -33.0M | -9.79M | -6.38M | -35.8M | -52.4M | -41.7M |
| Capital Expenditure | 976K | 2.07M | 1.82M | 663K | 517K | 913K | 2.52M | 995K | 159K | 562K | 1.13M |
| Free Cash Flow | -9.15M | 3.76M | -14.8M | -60.9M | -46.0M | -33.9M | -12.3M | -7.38M | -35.9M | -53.0M | -42.9M |
| Ratios | |||||||||||
| ROE | - | - | -608.9% | - | - | - | - | - | - | - | - |
| ROA | -24.4% | -20.7% | -70.7% | -84.4% | -88.7% | -113.8% | -95.3% | -13.7% | -43.5% | -52.2% | -53.0% |
| Net Profit Margin | -18.5% | -13.4% | -91.0% | -125.9% | -121.7% | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% | -132.4% |
| Debt to Equity | - | - | 4.68x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aquestive Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 3.00K | 0.00 | - |
| 2021 | - | - | - |
| 2020 | USD 99.0K | 0.00 | - |
| 2019 | USD 2.83M | 0.11 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Aquestive Therapeutics Inc
- Insiders 10.79%
- Institutions 57.62%
- Public & others 31.59%
- Shares outstanding 126M
- Free float 113M
Top funds holding AQST.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.40M | 2.71% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.76M | 2.19% | 0.00% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 1.39M | 1.11% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 1.35M | 1.07% | +76.06% | Oct 2026 |
| Fidelity Small Cap Index | 1.19M | 0.94% | +1.24% | Aug 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 1.17M | 0.93% | +2.88% | Oct 2026 |
| Wasatch Micro Cap | 642K | 0.51% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 642K | 0.51% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 627K | 0.50% | +1.05% | Sep 2026 |
| Fidelity Extended Market Index | 539K | 0.43% | +15.60% | Sep 2026 |
| Federated Hermes MDT Small Cap Growth IS | 530K | 0.42% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 379K | 0.30% | -0.38% | Oct 2026 |
| iShares Micro-Cap ETF | 327K | 0.26% | 0.00% | Oct 2026 |
| Simplify Propel Opportunities ETF | 279K | 0.22% | 0.00% | Oct 2026 |
| Federated Hermes MDT Small Cap Core ETF | 274K | 0.22% | -3.63% | Oct 2026 |
| Schwab Small Cap Index | 263K | 0.21% | 0.00% | Sep 2026 |
| Truvalue Glb Phrmctl Blgcl Eq (QDII) A | 210K | 0.17% | -59.67% | Jun 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 210K | 0.17% | -6.50% | Sep 2026 |
| Fidelity Total Market Index | 203K | 0.16% | +20.47% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 202K | 0.16% | 0.00% | Sep 2026 |
Top institutions holding AQST.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bratton Capital Management, L.P. | 9.81M | 7.82% | 0.00% | Sep 2026 |
| BlackRock Inc | 8.07M | 6.43% | +7.46% | Jun 2026 |
| RTW INVESTMENTS, LLC | 7.43M | 5.92% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.58M | 3.65% | +3.17% | Jun 2026 |
| Federated Hermes Inc | 3.11M | 2.48% | +5.86% | Jun 2026 |
| State Street Corp | 2.93M | 2.33% | +15.00% | Jun 2026 |
| Geode Capital Management, LLC | 2.62M | 2.09% | +8.92% | Jun 2026 |
| Samsara BioCapital, LLC | 2.50M | 1.99% | 0.00% | Jun 2026 |
| Bank of America Corp | 1.67M | 1.33% | -30.63% | Jun 2026 |
| Sio Capital Management, LLC | 1.49M | 1.18% | -22.71% | Jun 2026 |
| Propel Bio Management LLC | 1.44M | 1.15% | +102.87% | Jun 2026 |
| Wasatch Advisors LP | 1.39M | 1.10% | +57.78% | Jun 2026 |
| Two Sigma Investments LLC | 1.28M | 1.02% | +12.45% | Jun 2026 |
| Nuveen, LLC | 1.22M | 0.97% | +379.44% | Jun 2026 |
| Janney Montgomery Scott LLC | 1.11M | 0.88% | +1.57% | Jun 2026 |
| Wells Fargo & Co | 1.09M | 0.87% | +5.26% | Jun 2026 |
| Commonwealth Equity Services, LLC | 1.05M | 0.83% | -3.37% | Jun 2026 |
| Barclays PLC | 997K | 0.79% | +24.71% | Jun 2026 |
| Blue Owl Capital Holdings LP | 943K | 0.75% | -30.05% | Jun 2026 |
| Northern Trust Corp | 831K | 0.66% | +13.47% | Jun 2026 |
Aquestive Therapeutics Inc company profile
- Company name
- Aquestive Therapeutics Inc
- Ticker
- AQST.US
- Exchange
- USA Stocks
- Listed since
- Jul 25, 2018
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 147
- Fiscal year end
- December
- Address
- 184 Liberty Corner Road, Warren, NJ, United States, 07059
- Phone
- 908 941 1900
- Website
- aquestive.com
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Aquestive Therapeutics Inc management
10- Mr. Daniel BarberCEO, President & Director · born 1976
- Mr. A. Ernest Toth Jr.Senior VP & CFO · born 1959
- Ms. Lori J. Braender BSBA, Esq., J.D.Corporate Secretary · born 1956
- Ms. Cassie JungChief Operating Officer · born 1979
- Mr. Thomas A. ZalewskiChief Legal Officer & Chief Compliance Officer · born 1972
- Mr. Peter E. BoydSenior Vice President of Information Technology & Chief People Officer · born 1966
- Dr. Matthew Greenhawt B.Sc., M.B.A., M.D.Chief Medical Officer · born 1974
- Ms. Sherry KorczynskiChief Commercial Officer · born 1970
- Dr. Melina T. Cioffi Pharm.D.Senior Vice President of Regulatory Affairs · born 1983
- Dr. Matthew William Davis M.D., R.Ph.Chief Development Officer · born 1966